Hepatic resection for metastatic gynecologic carcinomas
- PMID: 9234920
- DOI: 10.1006/gyno.1997.4727
Hepatic resection for metastatic gynecologic carcinomas
Abstract
Objective: To report a series of cases of hepatic resection for metastatic gynecologic carcinomas.
Methods: We reviewed the records of all patients who underwent hepatic resection for metachronous liver metastases from gynecologic carcinomas at our institution from 1986 to 1996.
Results: Twelve patients were identified with a median age of 60 years (range 30-73 years). The primary sites of carcinoma were as follows: ovary, 7 (58%); cervix, 2 (17%); endometrium, 2 (17%); and fallopian tube, 1 (8%). The median disease-free interval before the diagnosis of liver metastasis was 32 months (range 1-243 months). The types of liver resections were as follows: trisegmentectomy, 4 (33%); lobectomy, 4 (33%); segmentectomy, 3 (25%); and wedge resection, 1 (8%). To remove all visible tumor with adequate margins, additional surgery included the following: resection of a portion of the diaphragm, 5 (42%); wedge resection of the right lung, 3 (25%); resection of a portion of the pericardium, 2 (17%); and adrenalectomy, 1 (8%). One patient (8%) had pulmonary wedge resections of bilateral pulmonary metastases. There was no perioperative mortality. Ten patients (83%) received additional chemotherapy. With a median follow-up of 25 months (range 8-94 months), the median survival time is 27 months. Three patients (25%) have no evidence of tumor recurrence at 8, 17, and 38 months of follow-up. Nine patients (75%) have had tumor recurrence at a median of 12 months from the time of surgery.
Conclusions: Hepatic resection of metachronous metastases from gynecologic carcinomas can be performed safely and may help prolong survival in carefully selected patients.
Similar articles
-
Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.Ann Thorac Surg. 2006 Jun;81(6):2004-7. doi: 10.1016/j.athoracsur.2006.01.068. Ann Thorac Surg. 2006. PMID: 16731120
-
Survival after repeat hepatic resection for recurrent colorectal metastases.Hepatogastroenterology. 1999 Mar-Apr;46(26):1065-70. Hepatogastroenterology. 1999. PMID: 10370668
-
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.Eur J Surg Oncol. 2004 Sep;30(7):759-64. doi: 10.1016/j.ejso.2004.05.009. Eur J Surg Oncol. 2004. PMID: 15296990
-
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085. Ann Thorac Surg. 2004. PMID: 15464470 Review.
-
[Individualized systemic gynecologic tumor therapy in gynecology].Gynakologe. 1988 Dec;21(4):319-22. Gynakologe. 1988. PMID: 3061893 Review. German. No abstract available.
Cited by
-
Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.Gynecol Oncol Res Pract. 2016 Jun 17;3:7. doi: 10.1186/s40661-016-0028-3. eCollection 2016. Gynecol Oncol Res Pract. 2016. PMID: 27330821 Free PMC article. Review.
-
Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes.Clin Exp Metastasis. 2020 Feb;37(1):107-113. doi: 10.1007/s10585-019-10007-0. Epub 2019 Nov 22. Clin Exp Metastasis. 2020. PMID: 31758289
-
Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach.World J Hepatol. 2021 Sep 27;13(9):1122-1131. doi: 10.4254/wjh.v13.i9.1122. World J Hepatol. 2021. PMID: 34630879 Free PMC article. Review.
-
Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers.Semin Intervent Radiol. 2018 Mar;35(1):29-34. doi: 10.1055/s-0038-1636518. Epub 2018 Apr 5. Semin Intervent Radiol. 2018. PMID: 29628613 Free PMC article. Review.
-
Reported outcome factors for hepatic metastasectomy.J Gastrointest Surg. 2006 Feb;10(2):155-160. doi: 10.1016/j.gassur.2005.09.021. J Gastrointest Surg. 2006. PMID: 16622977 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical